Abstract 2683
Background
VT1021 is a cyclic pentapeptide that functions as a potent inducer of thrombospondin-1 (Tsp-1) expression in the tumor microenvironment (TME). By triggering the production of Tsp-1, VT1021 reprograms the TME from one that is immune-suppressive and tumor-promoting, to one that activates the adaptive immune system and is tumor-inhibiting. Tsp-1 reprograms the TME to: (i) induce apoptosis in tumor cells that express CD36 on their cell surface, (ii) convert macrophages from M2 to M1 polarization, which promotes phagocytosis and blunts immunosuppression, and (iii) inhibit angiogenesis. Preclinical studies have shown robust anti-tumor activities of VT1021 in animal models of ovarian, pancreatic and breast cancer, including complete tumor regression and reprogramming of the immune TME.
Methods
This study is a first-in-human, phase 1, open-label, multicenter dose escalation (Part 1) study with dose expansion (Part 2) in advanced solid tumors. The primary objectives are to assess the safety and tolerability of VT1021, assess dose-limiting toxicities (DLT), and determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Secondary objectives include the evaluation of pharmacokinetics (PK) and the pharmacodynamic (PD) effects of VT1021 in tumor biopsies, and assessment of preliminary efficacy.
Results
In Part 1 of the study, 27 patients received 0.5-6.6 mg/kg of VT1021 twice weekly to determine the MTD and RP2D for expansion. One patient developed a grade 3 infusion reaction and 2 patients developed a grade 2 infusion reaction. Premedication with steroids and antihistamines has prevented subsequent significant infusion reactions. Other drug-related AEs included grade 1-2 fatigue, myalgia and dizziness. Dose proportionality was observed in PK analysis. Evidence of Tsp-1 expression, as measured by IHC on tumor biopsies, was observed. Prolonged stable disease was observed in 2 patients including ovarian and colorectal cancer. In Part 2 of the study, 75 patients will be enrolled based on tumor type and CD36 expression.
Conclusions
Through all doses tested thus far, VT1021 has been shown to be safe for patients and induces expression of Tsp-1.
Clinical trial identification
NCT03364400 December 6, 2017.
Editorial acknowledgement
Legal entity responsible for the study
Vigeo Therapeutics, Inc.
Funding
Vigeo Therapeutics, Inc.
Disclosure
S. Wang: Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Therapeutics, Inc. K. Kerstein: Full / Part-time employment: Vigeo Therapeutics, Inc. G. Berk: Advisory / Consultancy: Vigeo Therapeutics, Inc. M.J. Cieslewicz: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Vigeo Therapeutics. J. Watnick: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment, Officer / Board of Directors: Vigeo Therapeutics, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract